Company news

VYNE Therapeutics Inc. news in 2023

VYNE Therapeutics Inc.'s news releases, calls and decks from 2023, newest first.

View company

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 12, 2023

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

November 6, 2023

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

October 31, 2023

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

October 29, 2023

VYNE Therapeutics Announces Private Placement of $88 Million

October 29, 2023

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

October 29, 2023

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 13, 2023

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

April 30, 2023

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

April 18, 2023

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

March 29, 2023

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

March 8, 2023

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

February 27, 2023

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

February 14, 2023

VYNE Therapeutics Announces Reverse Stock Split

February 9, 2023

VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

January 8, 2023

Decks in 2023